Castle Biosciences (CSTL) Free Cash Flow (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Free Cash Flow data on file, last reported at -$34.6 million in Q1 2026.

• Quarterly Free Cash Flow fell 273.76% year-over-year to -$34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.9 million (down 41.56% YoY) and the FY2025 annual result came in at $62.2 million, down 4.06% from the prior year.
• Free Cash Flow slipped to -$34.6 million in Q1 2026 per CSTL's latest filing, from $53.7 million in the prior quarter.
• The five-year high for Free Cash Flow was $53.7 million in Q4 2025, with the low at -$34.6 million in Q1 2026.
• Average Free Cash Flow over 5 years is $1.8 million, with a median of -$3.6 million recorded in 2022.
• Year-over-year, Free Cash Flow slumped 389.89% in 2022 and jumped 977.21% in 2024.
• Castle Biosciences' Free Cash Flow stood at -$3.6 million in 2022, then surged by 516.62% to $14.8 million in 2023, then soared by 205.02% to $45.1 million in 2024, then gained by 18.9% to $53.7 million in 2025, then plunged by 164.46% to -$34.6 million in 2026.
• Business Quant data shows CSTL's Free Cash Flow at -$34.6 million in Q1 2026, $53.7 million in Q4 2025, and $616000.0 in Q3 2025.